Amicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to “Buy”
StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) from a hold rating to a buy rating in a report published on Monday. Several other equities analysts have also weighed in on the stock. Cantor Fitzgerald restated an overweight rating and set a $20.00 price target on shares of Amicus Therapeutics in a research […]
More Stories
Ukraine Reports Crash of One of Its F-16s, Pilot Safe
By Victoria Friedman The Armed Forces of Ukraine said one of its F-16 fighter jets had crashed, and that the...
US Gas Prices Remain Elevated Amid Ongoing Middle East Tensions US Gas Prices Remain Elevated Amid Ongoing Middle East Tensions
By Naveen Athrappully Gasoline prices in the United States continue to remain high at over $4 per gallon as the...
Spain’s Ceuta Overwhelmed as Nearly 60,000 Illegal Immigrants Cross From Morocco in a Day
By Owen Evans Ceuta was overwhelmed overnight as the Spanish North African exclave faced a fresh wave of nearly 60,000...
Spain’s Mass Illegal Immigration Crisis: What to Know
By Troy Myers Tens of thousands of illegal immigrants crossed from Morocco into Spain in a single day, igniting worldwide...
Weekly Unemployment Claims Remain at Historically Low Levels
By Andrew Moran The number of Americans applying for unemployment benefits remained at historically low levels last week, as layoffs...
US Government Acquires Equity Stakes in 7 More Companies
By Andrew Moran The Department of Commerce said on July 29 it will allocate $874 million in incentives to bolster...